AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible

Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic

InflaRx N.V. a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the European Commission (EC) has granted marketing authorization under exceptional circumstances

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the clearance of its Investigational New Drug application

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced

Partner Therapeutics, Inc. (PTx) today announced a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to fund a phase 2 study

Johnson & Johnson today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S. Food and Drug Administration (FDA) for the treatment of antibody positive

Samsung Biologics a global contract development and manufacturing organization (CDMO), today announced to extend collaboration with LigaChem Biosciences (KOSDAQ: 141080) to provide antibody-drug conjugate (ADC) services.

Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient is living, non-genetically altered, allogeneic (“off-the-shelf”) immune cells, announces that it has entered into

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new Antibody-Drug-Conjugate (ADC) collaboration